

PANORAMA STUDY

...for nonproliferative diabetic retinopathy



PANORAMA STUDY

...for nonproliferative diabetic retinopathy

To investigate the safety and efficacy of intravitreal aflibercept (eylea) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy

INCLUSION / EXCLUSION CRITERIA:

- At least 18 years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe NPDR (DRSS levels 47 or 53) confirmed by the central reading center
- BCVA ETDRS letter score in the study eye of ≥ 69 letters (approximate Snellen equivalent of 20/40 or better)
- No presence of DME threatening the center of the macula in study eye
- No prior prp, focal, or grid laser photocoagulation in the study eye
- No prior systemic anti-VEGF treatment or IVT anti-VEGF treatment in the study eye

US-EYE-11801

CONTACT Havener Eye Institute Research Office • 614-293-5287 or • Research@osumc.edu
Kim Rickard
Laura Sladoje, Clinical Trial Manager • 614-293-9161